FiercePharma

ELIQUIS ® (apixaban) Approved in Europe for Prevention of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation

Only anticoagulant proven to show superior risk reductions versus warfarin in three important outcomes: stroke, major bleeding and all-cause death First approval in any market worldwide of ELIQUIS for ...
FiercePharma

Eliquis® (apixaban) Demonstrated Comparable Efficacy and Significantly Lower Rates of Major Bleeding in Patients Compared to Current Standard of Care for the Treatment of ...

Eliquis® (apixaban) Demonstrated Comparable Efficacy and Significantly Lower Rates of Major Bleeding in Patients Compared to Current Standard of Care for the Treatment of Acute Venous Thromboembolism ...
FierceBiotech

ELIQUIS® (apixaban) was Superior to Warfarin for the Reduction of Stroke or Systemic Embolism

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced the main results of the Phase 3 clinical trial ARISTOTLE, which ...
FierceBiotech

ELIQUIS® (apixaban) Meets Primary and Key Secondary Endpoints in Phase 3 ARISTOTLE Study

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) announced today topline results of the Phase 3 ARISTOTLE trial of ELIQUIS ®. In this ...
clinicaladvisor.com

Apixaban in Patients With ESRD and Atrial Fibrillation

Warfarin, blood thinner There are limited published data on the efficacy and safety of direct-acting oral anticoagulants (DOACs) in patients with end-stage renal disease (ESRD) on dialysis and atrial ...